Heather F. Jones

Heather F. Jones

Auto-generated profile, based on publicly available information

Heather F. Jones

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2018 in eLife
Verified
Journal Article
Open access
RGRon S Gejman
Ron S Gejman
ACAaron Y Chang
Aaron Y Chang
HJHeather F Jones
Heather F Jones
KDKrysta DiKun
Krysta DiKun
AHAbraham Ari Hakimi
Abraham Ari Hakimi
DSDavid A Scheinberg
David A Scheinberg
Tumors often co-exist with T cells that recognize somatically mutated peptides presented by cancer cells on major histocompatibility complex I (MHC-I). However, it is unknown why the immune system fails to eliminate immune-recognizable neoplasms before they manifest as frank disease. To understand the determinants of MHC-I peptide immunogenicity in nascent tumors, we tested the ability of thousands of MHC-I ligands to cause tumor subclone rejection in immunocompetent mice by use of a new ‘PresentER’ antigen presentation platform. Surprisingly, we show that immunogenic tumor antigens do not lead to immune-mediated cell rejection when the fraction of cells bearing each antigen (‘clonal fraction’) is low. Moreover, the clonal fraction necessary to lead to rejection of immunogenic tumor subclones depends on the antigen. These data indicate that tumor neoantigen heterogeneity has an underappreciated impact on immune elimination of cancer cells and has implications for the design of immunotherapeutics such as cancer vaccines.

17 March 2020 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
RGRon S. Gejman
Ron S. Gejman
HJHeather F. Jones
Heather F. Jones
MKMartin G. Klatt
Martin G. Klatt
ACAaron Y. Chang
Aaron Y. Chang
COClaire Y. Oh
Claire Y. Oh
DSDavid A. Scheinberg
David A. Scheinberg
T-cell receptor (TCR)–based therapeutic cells and agents have emerged as a new class of effective cancer therapies. These therapies work on cells that express intracellular cancer-associated proteins by targeting peptides displayed on MHC receptors. However, cross-reactivities of these agents to off-target cells and tissues have resulted in serious, sometimes fatal, adverse events. We have developed a high-throughput genetic platform (termed “PresentER”) that encodes MHC-I peptide minigenes for functional immunologic assays and determines the reactivities of TCR-like therapeutic agents against large libraries of MHC-I ligands. In this article, we demonstrated that PresentER could be used to identify the on-and-off targets of T cells and TCR-mimic (TCRm) antibodies using in vitro coculture assays or binding assays. We found dozens of MHC-I ligands that were cross-reactive with two TCRm antibodies and two native TCRs and that were not easily predictable by other methods.

16 February 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
RGRon S. Gejman
Ron S. Gejman
HJHeather F. Jones
Heather F. Jones
MKMartin G. Klatt
Martin G. Klatt
ACAaron Y. Chang
Aaron Y. Chang
COClaire Y. Oh
Claire Y. Oh
DSDavid A. Scheinberg
David A. Scheinberg
T cell receptor (TCR)-based therapeutic cells and agents have emerged as a new class of effective cancer therapeutics. These therapies work on cells that express intracellular cancer-associated proteins by targeting peptides displayed on major histocompatibility complex receptors. However, cross-reactivities of these agents to off-target cells and tissues have resulted in serious, sometimes fatal, adverse events. We have developed a high throughput genetic platform (termed “PresentER”) that encodes MHC-I peptide minigenes for functional immunological assays as well as for determining the reactivities of TCR-like therapeutic agents against large libraries of MHC-I ligands. In this report, we demonstrate that PresentER can be used to identify the on-and-off targets of T cells and TCR mimic antibodies using in vitro co-culture assays or binding assays. We find dozens of MHC-I ligands that are cross-reactive with two TCR mimic antibodies and two native TCRs and that are not easily predictable by other methods.

4 April 2023
Verified
Other
Open access
RGRon S. Gejman
Ron S. Gejman
HJHeather F. Jones
Heather F. Jones
MKMartin G. Klatt
Martin G. Klatt
ACAaron Y. Chang
Aaron Y. Chang
COClaire Y. Oh
Claire Y. Oh
DSDavid A. Scheinberg
David A. Scheinberg
T-cell receptor (TCR)–based therapeutic cells and agents have emerged as a new class of effective cancer therapies. These therapies work on cells that express intracellular cancer-associated proteins by targeting peptides displayed on MHC receptors. However, cross-reactivities of these agents to off-target cells and tissues have resulted in serious, sometimes fatal, adverse events. We have developed a high-throughput genetic platform (termed “PresentER”) that encodes MHC-I peptide minigenes for functional immunologic assays and determines the reactivities of TCR-like therapeutic agents against large libraries of MHC-I ligands. In this article, we demonstrated that PresentER could be used to identify the on-and-off targets of T cells and TCR-mimic (TCRm) antibodies using in vitro coculture assays or binding assays. We found dozens of MHC-I ligands that were cross-reactive with two TCRm antibodies and two native TCRs and that were not easily predictable by other methods.

4 April 2023
Verified
Other
Open access
RGRon S. Gejman
Ron S. Gejman
HJHeather F. Jones
Heather F. Jones
MKMartin G. Klatt
Martin G. Klatt
ACAaron Y. Chang
Aaron Y. Chang
COClaire Y. Oh
Claire Y. Oh
DSDavid A. Scheinberg
David A. Scheinberg
T-cell receptor (TCR)–based therapeutic cells and agents have emerged as a new class of effective cancer therapies. These therapies work on cells that express intracellular cancer-associated proteins by targeting peptides displayed on MHC receptors. However, cross-reactivities of these agents to off-target cells and tissues have resulted in serious, sometimes fatal, adverse events. We have developed a high-throughput genetic platform (termed “PresentER”) that encodes MHC-I peptide minigenes for functional immunologic assays and determines the reactivities of TCR-like therapeutic agents against large libraries of MHC-I ligands. In this article, we demonstrated that PresentER could be used to identify the on-and-off targets of T cells and TCR-mimic (TCRm) antibodies using in vitro coculture assays or binding assays. We found dozens of MHC-I ligands that were cross-reactive with two TCRm antibodies and two native TCRs and that were not easily predictable by other methods.

4 April 2023
Verified
Other
Open access
RGRon S. Gejman
Ron S. Gejman
HJHeather F. Jones
Heather F. Jones
MKMartin G. Klatt
Martin G. Klatt
ACAaron Y. Chang
Aaron Y. Chang
COClaire Y. Oh
Claire Y. Oh
DSDavid A. Scheinberg
David A. Scheinberg
Supplementary Tables and Figures